Citadel Advisors’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $450K | Buy |
+266,340
| New | +$1.17M | ﹤0.01% | 9556 |
|
|
2025
Q4 | – | Sell |
-152,254
| Closed | -$782K | – | 12556 |
|
|
2025
Q3 | $795K | Buy |
152,254
+139,800
| +1,123% | +$729K | ﹤0.01% | 8042 |
|
|
2025
Q2 | $47.7K | Buy |
+12,454
| New | +$32.2K | ﹤0.01% | 11791 |
|
|
2025
Q1 | – | Sell |
-85,642
| Closed | -$506K | – | 14398 |
|
|
2024
Q4 | $427K | Buy |
85,642
+31,491
| +58% | +$162K | ﹤0.01% | 8909 |
|
|
2024
Q3 | $292K | Buy |
54,151
+44,587
| +466% | +$212K | ﹤0.01% | 9393 |
|
|
2024
Q2 | $31.7K | Sell |
9,564
-45,684
| -83% | -$179K | ﹤0.01% | 12210 |
|
|
2024
Q1 | $181K | Sell |
55,248
-12,481
| -18% | -$41.1K | ﹤0.01% | 10483 |
|
|
2023
Q4 | $238K | Sell |
67,729
-222,070
| -77% | -$685K | ﹤0.01% | 9611 |
|
|
2023
Q3 | $1.94M | Buy |
289,799
+134,651
| +87% | +$999K | ﹤0.01% | 5278 |
|
|
2023
Q2 | $1.3M | Sell |
155,148
-33,095
| -18% | -$326K | ﹤0.01% | 5930 |
|
|
2023
Q1 | $1.87M | Sell |
188,243
-521,910
| -73% | -$3.69M | ﹤0.01% | 5529 |
|
|
2022
Q4 | $4.94M | Sell |
710,153
-953,975
| -57% | -$5.45M | ﹤0.01% | 3883 |
|
|
2022
Q3 | $8.89M | Sell |
1,664,128
-654,050
| -28% | -$3.92M | ﹤0.01% | 2944 |
|
|
2022
Q2 | $9.25M | Sell |
2,318,178
-161,358
| -7% | -$555K | ﹤0.01% | 2788 |
|
|
2022
Q1 | $11M | Buy |
2,479,536
+2,190,919
| +759% | +$8.73M | ﹤0.01% | 2807 |
|
|
2021
Q4 | $1.15M | Buy |
288,617
+240,484
| +500% | +$1.83M | ﹤0.01% | 7593 |
|
|
2021
Q3 | $423K | Buy |
48,133
+20,056
| +71% | +$184K | ﹤0.01% | 10274 |
|
|
2021
Q2 | $318K | Sell |
28,077
-229,315
| -89% | -$2.76M | ﹤0.01% | 11118 |
|
|
2021
Q1 | $3.06M | Sell |
257,392
-1,068,295
| -81% | -$12.3M | ﹤0.01% | 5395 |
|
|
2020
Q4 | $9.09M | Buy |
1,325,687
+296,868
| +29% | +$2.08M | ﹤0.01% | 2778 |
|
|
2020
Q3 | $7.62M | Buy |
1,028,819
+975,512
| +1,830% | +$6.3M | ﹤0.01% | 2614 |
|
|
2020
Q2 | $223K | Buy |
53,307
+15,101
| +40% | +$55.2K | ﹤0.01% | 8365 |
|
|
2020
Q1 | $95K | Buy |
38,206
+8,843
| +30% | +$39.8K | ﹤0.01% | 8658 |
|
|
2019
Q4 | $171K | Buy |
29,363
+12,148
| +71% | +$70.2K | ﹤0.01% | 8290 |
|
|
2019
Q3 | $91K | Buy |
17,215
+5,810
| +51% | +$31.3K | ﹤0.01% | 8529 |
|
|
2019
Q2 | $68K | Sell |
11,405
-21,503
| -65% | -$162K | ﹤0.01% | 8647 |
|
|
2019
Q1 | $297K | Buy |
32,908
+19,960
| +154% | +$170K | ﹤0.01% | 7623 |
|
|
2018
Q4 | $107K | Buy |
+12,948
| New | +$133K | ﹤0.01% | 8217 |
|
|
2018
Q3 | – | Sell |
-11,409
| Closed | -$91K | – | 9156 |
|
|
2018
Q2 | $91K | Buy |
11,409
+159
| +1% | +$1.27K | ﹤0.01% | 8277 |
|
|
2018
Q1 | $84K | Buy |
+11,250
| New | +$85.4K | ﹤0.01% | 7773 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Citadel Advisors's ALDX Position: Q1 2026 in Review
Citadel Advisors opened a new position in Aldeyra Therapeutics (ALDX) in Q1 2026: 266,340 shares worth $450K. The stake represents ﹤0.01% of the portfolio and ranks #9556 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ALDX as recently as Q3 2025.
Citadel Advisors first reported a position in ALDX in Q1 2018 and has held it in 30 quarters since. The position peaked at $11M in Q1 2022. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Citadel Advisors held 266,340 shares of Aldeyra Therapeutics worth $450K as of Q1 2026.
- Aldeyra Therapeutics was a new Citadel Advisors position in Q1 2026.
- Aldeyra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9556 holding.
- Citadel Advisors first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 30 quarters since.
- Citadel Advisors's Aldeyra Therapeutics position peaked at $11M in Q1 2022.
- 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.